Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3

Conditions

Lymphoma, B-Cell 6Lymphoma, Non-Hodgkin 4Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 2Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Dendritic Cell Sarcoma, Interdigitating 1

Interventions

Rituximab 416Cyclophosphamide 348Vincristine 173Prednisone 172Doxorubicin 168Etoposide 160Peripheral Blood Stem Cell Transplantation 114Filgrastim 108Lenalidomide 97fludarabine phosphate 96Radiotherapy 80Cytarabine 80Gemcitabine 73Melphalan 66Mycophenolic Acid 64Cyclosporine 60Methotrexate 59Busulfan 57Ifosfamide 55Carmustine 55fludarabine 50Tacrolimus 50Whole-Body Irradiation 49Carboplatin 49polatuzumab vedotin 44Oxaliplatin 44Dexamethasone 44Antilymphocyte Serum 42ibrutinib 40Bendamustine Hydrochloride 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × relmacabtagene autoleucel × Clear all
NCT07077512 2026-01-21

Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma

Sun Yat-sen University

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT06093841 2025-02-11

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 2 Active not recruiting
46 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04812691 2023-11-22

CD19-targeted CAR T Cells (JWCAR029) for Primary Refractory Diffuse Large B Cell Lymphoma

Shanghai Ming Ju Biotechnology Co., Ltd.

Phase 1 Completed
12 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡